Cetuximab + Gemox in Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2009

Conditions
UnresectableLocally AdvancedMetastatic
Interventions
DRUG

Cetuximab + Gemcitabine + Oxaliplatin

Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks

Trial Locations (1)

1030

KH Rudolfstiftung, Vienna

All Listed Sponsors
lead

Association of Research on the Biology of Liver Tumors

OTHER

NCT01216345 - Cetuximab + Gemox in Biliary Tract Cancer | Biotech Hunter | Biotech Hunter